psalexa
P&S Market Research - A market research firm

Neurofibromatoses Type I Therapeutics Pipeline Analysis

Neurofibromatoses Type I Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11249
Available Format:

Neurofibromatoses type I is a genetic condition characterized by the growth of tumours along the nerves in the brain, skin and other parts of the body, and skin pigmentation. Neurofibromatoses is an autosomal dominant disorder which is caused by the mutation in NF1 gene, a tumour suppressor gene, that encodes protein to stop growing and dividing in an uncontrolled manner. The condition usually begins in early childhood, which causes flat patches on the skin that are darker. In later childhood, freckles can be developed in the underarms and groins. The signs and symptoms of neurofibromatoses type I include hypertension, macrocephaly, short stature, skeletal abnormalities, autism spectrum disorder, learning disabilities, and seizures. Universitaire Ziekenhuizen Leuven is in the process of developing lamotrigine as a sodium channel antagonist for the treatment of neurofibromatoses type I. University of Utah is in the process of developing cholecalciferol for the treatment of neurofibromatoses type I. Some of the companies and universities having the pipeline of neurofibromatoses include Universitaire Ziekenhuizen Leuven, Vanderbilt University, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry